These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 38621153

  • 1. Telehealth Utilization for Opioid Use Disorder: A Nationwide Analysis Before and After the COVID-19 Public Health Emergency Declaration.
    Lewis KN, Zhang D, Corrales G, Eswaran H, Hayes CJ, Gressler LE.
    Telemed J E Health; 2024 Jun; 30(7):e1980-e1989. PubMed ID: 38621153
    [No Abstract] [Full Text] [Related]

  • 2. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
    Livingston NA, Sarpong A, Sistad R, Roth C, Banducci AN, Simpson T, Hyde J, Davenport M, Weisberg R.
    J Subst Use Addict Treat; 2024 Jan; 156():209188. PubMed ID: 37866437
    [Abstract] [Full Text] [Related]

  • 3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM.
    JAMA Psychiatry; 2022 Oct 01; 79(10):981-992. PubMed ID: 36044198
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Trends in Opioid Use Disorder Outpatient Treatment and Telehealth Utilization Before and During the COVID-19 Pandemic.
    Tormohlen KN, Eisenberg MD, Fingerhood MI, Yu J, McCourt AD, Stuart EA, Rutkow L, Quintero L, White SA, McGinty EE.
    Psychiatr Serv; 2024 Jan 01; 75(1):72-75. PubMed ID: 37461819
    [Abstract] [Full Text] [Related]

  • 7. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV, Engel-Rebitzer E, Dolan A, Oyekanmi K, Mandell D, Meisel Z, South E, Lowenstein M.
    Harm Reduct J; 2021 Nov 25; 18(1):119. PubMed ID: 34823538
    [Abstract] [Full Text] [Related]

  • 8. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH, Cales SC, Shreffler J, Huecker MR.
    J Subst Abuse Treat; 2022 Feb 25; 133():108543. PubMed ID: 34210567
    [Abstract] [Full Text] [Related]

  • 9. Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs.
    Austin AE, Tang L, Kim JY, Allen L, Barnes AJ, Chang CH, Clark S, Cole ES, Durrance CP, Donohue JM, Gordon AJ, Huskamp HA, McDuffie MJ, Mehrotra A, Mohamoud S, Talbert J, Ahrens KA, Applegate M, Hammerslag LR, Lanier P, Tossone K, Zivin K, Burns ME.
    JAMA Health Forum; 2023 Jun 02; 4(6):e231422. PubMed ID: 37327009
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. How Does Telehealth Expansion Change Access to Healthcare for Patients With Different Types of Substance Use Disorders?
    Tilhou AS, Burns M, Chachlani P, Chen Y, Dague L.
    Subst Use Addctn J; 2024 Jul 02; 45(3):473-485. PubMed ID: 38494728
    [Abstract] [Full Text] [Related]

  • 12. Implementing a low-threshold audio-only telehealth model for medication-assisted treatment of opioid use disorder at a community-based non-profit organization in Washington, D.C.
    Yeo EJ, Kralles H, Sternberg D, McCullough D, Nadanasabesan A, Mayo R, Akselrod H, Catalanotti J.
    Harm Reduct J; 2021 Dec 09; 18(1):127. PubMed ID: 34886850
    [Abstract] [Full Text] [Related]

  • 13. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.
    Haggerty T, Khodaverdi M, Dekeseredy P, Wood N, Hendricks B, Peklinsky J, Sedney CL.
    J Subst Abuse Treat; 2022 May 09; 136():108687. PubMed ID: 34903397
    [Abstract] [Full Text] [Related]

  • 14. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
    Eugenia Socias M, Choi JC, Fairbairn N, Johnson C, Wilson D, Debeck K, Brar R, Hayashi K.
    Int J Drug Policy; 2023 Aug 09; 118():104075. PubMed ID: 37271070
    [Abstract] [Full Text] [Related]

  • 15. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ, Ristau JT, Snyder H, Surlyn C, Eveland J, Smith-Bernardin S, Knight KR.
    Subst Abus; 2021 Aug 09; 42(2):205-212. PubMed ID: 33684331
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study.
    Bailey SR, Wyte-Lake T, Lucas JA, Williams S, Cantone RE, Garvey BT, Hallock-Koppelman L, Angier H, Cohen DJ.
    Subst Use Misuse; 2023 Aug 09; 58(9):1143-1151. PubMed ID: 37170596
    [Abstract] [Full Text] [Related]

  • 18. Telehealth in opioid use disorder treatment: policy considerations for expanding access to care.
    Niyibizi A, Haveric A, Irio G.
    J Osteopath Med; 2024 Apr 01; 124(4):179-181. PubMed ID: 37976470
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.